Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Bavarian Nordic produces one of the only vaccines for mpox and its shots are the only ones licensed for the disease in the U.S. and European Union.

Bavarian Nordic CEO Paul Chaplin told STAT that 2 million doses of Jynneos vaccine could be produced this year, 8 million in 2025, to protect against mpox. Skip to Main Content.

The WHO’s declaration of an emergency has caused Bavarian Nordic’s shares to jump over 40%. The company's shares are up 51% since the start of the year, with its market cap at $3.28 billion.

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Bavarian Nordic Gets $63 Million US Government Order for Small Pox, Mpox Vaccine (Reuters) - Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional ...

Bavarian Nordic's vaccine has been used worldwide since 2022, after U.S. and European regulators backed it for use against a different strain of mpox that spread globally in 2022.

Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa's top public health body, after the body declared an emergency.